title: Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
abstract: A cisplatin-resistant cell line, SBC-3/CDDP, was established from a human small-cell lung cancer cell line, SBC-3. The SBC-3/CDDP cells were 13.1-fold more resistant to cisplatin than the parent SBC-3 cells. We investigated the cellular changes of this cell line with regard to the development of resistance to cisplatin. The SBC-3/CDDP cells showed various characteristics as follows: a) increased intracellular glutathione and glutathione S-transferase content b) decreased intracellular accumulation of cisplatin, c) increased topoisomerase I activity and the same topoisomerase II activity as the parent SBC-3 cells, and 4) strong cross-resistance to the platinum analogues and mitomycin C, moderate cross-resistance to 7-ethyl-10-hydroxy-camptothecin (SN-38), 4-hydroperoxy cyclophosphamide, etoposide, Adriamycin and methotrexate, and collateral sensitivity to vinca alkaloids and 5-fluorouracil. From these observations, the SBC-3/CDDP cells could be useful as a well characterized cisplatin-resistant cell line, and the resistance pattem in this cell line will give us much information for eradication of cisplatin-resistant tumor cells.
authors.affiliation: Second Department of Medicine, Okayama University Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Moritaka
authors.forename: K
authors.initials: K
authors.lastname: Kiura
authors.forename: H
authors.initials: H
authors.lastname: Ueoka
authors.forename: M
authors.initials: M
authors.lastname: Tabata
authors.forename: Y
authors.initials: Y
authors.lastname: Segawa
authors.forename: T
authors.initials: T
authors.lastname: Shibayama
authors.forename: N
authors.initials: N
authors.lastname: Takigawa
authors.forename: T
authors.initials: T
authors.lastname: Ohnoshi
authors.forename: M
authors.initials: M
authors.lastname: Harada
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology*; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005978:Glutathione / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014407:Tumor Cells, Cultured; D014750:Vincristine / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D014750:Vincristine; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; D005978:Glutathione; D002945:Cisplatin